Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-03-15 Earnings Release
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Annual financial report
Earnings Release Classification · 1% confidence The document is explicitly titled "2015 Full-Year Results and Progress Report" and reports financial results for the year ended December 31, 2015. It contains detailed financial tables (Income Statement and Balance Sheet) and management discussion regarding operations, R&D progress, and outlook. This content aligns perfectly with the definition of a comprehensive annual report, which is typically filed as a 10-K in the US context, or the equivalent comprehensive annual filing for non-US companies reporting full-year performance. Although it mentions the '2015 financial report published on ABIVAX's website' on April 26th, the current document itself contains the full results and detailed analysis, making it the Annual Report (10-K equivalent) rather than just a publication announcement (RPA). FY 2015
2016-03-15 English
ABIVAXs neuartiger Ansatz zur Behandlung von HIV-Infektionen zeigt Patientensicherheit und ersten Nachweis anti-viraler Aktivitat in Phase-IIa-Studie
Earnings Release Classification · 1% confidence The document is a press release dated February 25, 2016, announcing positive Phase IIa study results for ABIVAX's drug candidate ABX464 in treating HIV infections. It details study objectives, patient cohorts, dosage, observed antiviral activity, safety profile, and plans for a second Phase IIa study. This content structure—announcing clinical trial results and future plans in a news format, often referencing a presentation at a conference (CROI)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses specifically on the initial announcement of clinical trial results (key highlights and initial data presentation) rather than being a comprehensive quarterly/interim report (IR) or a full transcript (CT), the most appropriate classification is Earnings Release (ER), as clinical trial updates often serve as the primary 'earnings' news for biotech/pharma companies during development phases. It is not a formal regulatory report like a 10-K or AR, nor is it a simple announcement of a report's publication (RPA). Q1 2016
2016-02-25 German
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is a press release dated February 25th, 2016, announcing positive data from a Phase IIa clinical study for the drug ABX464 in HIV treatment-naïve patients, presented at the Conference for Retroviruses and Opportunistic Infections (CROI). It details study objectives, results (viral load reduction, safety profile), and future plans (a second Phase IIa trial). This content aligns perfectly with an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses on presenting key results and updates rather than being a comprehensive annual/interim report (10-K or IR), ER is the most appropriate classification for a results announcement. It is not a transcript (CT), a formal regulatory filing like 10-K, or a management discussion (MDA), but rather the initial public announcement of results. FY 2016
2016-02-25 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 25, 2016, announcing positive preliminary safety and antiviral activity results from an ABIVAX Phase IIa clinical study for their HIV treatment candidate, ABX464. It details study objectives, patient cohorts, dosage, observed viral load reduction, side effects, and plans for a second Phase IIa trial. This content structure—announcing clinical trial results and future plans via a formal press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is focused on presenting clinical trial data and results (not just financial highlights), and it is not a full regulatory report (like 10-K or IR), the most fitting category is 'Earnings Release' (ER), as clinical trial updates often accompany or substitute for quarterly financial updates in biotech/pharma, or it could be classified as a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the detailed nature of the results presentation, ER is a strong fit, as these releases often contain the key operational/clinical highlights that drive investor interest, similar to financial highlights. However, since the primary focus is the presentation of scientific/clinical data at a conference (CROI), and it is not explicitly labeled as an 'Earnings Release' but rather a general corporate update announcing study results, the most appropriate general category for significant, non-standard disclosures that are not explicitly defined elsewhere is 'Regulatory Filings' (RNS). Upon review of the definitions, 'ER' is for initial announcements of *financial* results. This document is announcing *clinical* results. Therefore, RNS (Regulatory Filings / miscellaneous announcements) is the safest fallback for a significant clinical data announcement that doesn't fit the other specific categories like 10-K, IR, or ER (which is financial). Given the context of a major data presentation at a conference, it functions as a key corporate update, making RNS the best fit among the available options for non-financial, non-standard reports.
2016-02-25 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Notice of Dividend Amount Classification · 1% confidence The document provides specific information regarding the total number of shares and voting rights ('nombre total de droits de vote et d'actions') as of a specific date (31/1/2016). It explicitly references French regulatory articles (Article L. 233-8 II du code de commerce and Article 223-16 du règlement général de l'Autorité des marchés financiers - AMF). This type of mandatory disclosure, detailing share structure and voting power, is typically classified as a general regulatory filing or a specific notification related to share capital/ownership changes. Since there is no specific code for 'Voting Rights Disclosure' outside of DVA (which is for voting *results*), and it is not a major shareholding notification (MRQ, which is for crossing ownership thresholds), the most appropriate general category for mandatory regulatory disclosures that don't fit elsewhere is RNS (Regulatory Filings). However, given the content is purely about the capital structure and voting rights calculation, it is a specific regulatory disclosure. In the context of the provided definitions, this is a mandatory disclosure related to share capital structure, which often falls under general regulatory announcements. Given the options, RNS is the best fit as a general regulatory filing notification.
2016-02-18 French
ABIVAX nimmt an RBC Capital Markets 2016 Healthcare Conference in New York und an der Credit Suisse Healthcare Conference in London teil
Regulatory Filings Classification · 1% confidence The document is a short news release dated February 11, 2016, announcing that the company ABIVAX will be participating in two upcoming industry conferences (RBC Capital Markets 2016 Healthcare Conference and Credit Suisse Healthcare Conference). It details the dates, locations, and types of interactions (fireside chat, one-on-one meetings) planned for management. This type of announcement, which informs investors about management's schedule for engaging with analysts and investors at industry events, is best classified as a general corporate announcement or investor relations activity. Since there is no specific category for 'Conference Participation Announcement,' and it is not a formal regulatory filing like 10-K, ER, or IR, it falls under the general regulatory/corporate news category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate news that doesn't fit a specific financial report or event type, although 'Investor Presentation' (IP) is related to investor engagement, this document is an announcement *about* participation, not the presentation itself. Therefore, RNS is the best fit as a general corporate news item.
2016-02-11 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.